1. Home
  2. RYTM vs DOCS Comparison

RYTM vs DOCS Comparison

Compare RYTM & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$115.20

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Logo Doximity Inc.

DOCS

Doximity Inc.

N/A

Current Price

$33.46

Market Cap

5.9B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
RYTM
DOCS
Founded
2008
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.9B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
RYTM
DOCS
Price
$115.20
$33.46
Analyst Decision
Strong Buy
Hold
Analyst Count
19
21
Target Price
★ $140.12
$31.50
AVG Volume (30 Days)
1.5M
★ 2.4M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 28.34
N/A
EPS
N/A
★ 0.31
Revenue
N/A
★ $644,863,000.00
Revenue This Year
$73.80
$5.49
Revenue Next Year
$73.86
$6.26
P/E Ratio
★ N/A
$107.48
Revenue Growth
N/A
★ 13.05
52 Week Low
$74.50
$17.15
52 Week High
$122.20
$51.85

Technical Indicators

Market Signals
Indicator
RYTM
DOCS
Relative Strength Index (RSI) 65.94 59.37
Support Level $82.31 $23.71
Resistance Level $119.75 $34.71
Average True Range (ATR) 6.84 1.42
MACD 2.19 -0.23
Stochastic Oscillator 94.00 70.28

Price Performance

Historical Comparison
RYTM
DOCS

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About DOCS Doximity Inc.

Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.

Share on Social Networks: